ZOCOR Tablets

  • Name:

    ZOCOR Tablets

  • Company:
    info
  • Active Ingredients:

    Simvastatin

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 13/11/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 13/11/2019

Click on this link to Download PDF directly

MSD Ireland (Human Health) Limited

MSD Ireland (Human Health) Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Neoclarityn Tablets Active Ingredients Desloratadine
Medicine Name Noxafil 100mg Gastro-resistant Tablets Active Ingredients Posaconazole
Medicine Name Noxafil 300 mg concentrate for solution for infusion Active Ingredients Posaconazole
Medicine Name Noxafil 40 mg/ml oral suspension Active Ingredients Posaconazole
Medicine Name Nuvaring Active Ingredients Ethinylestradiol, Etonogestrel
Medicine Name Orgalutran Active Ingredients Ganirelix
Medicine Name Pifeltro 100 mg film-coated tablets Active Ingredients Doravirine
Medicine Name PNEUMOVAX 23 solution for injection in pre-filled syringe Active Ingredients Pneumococcal polysaccharide vaccine
Medicine Name PROSCAR 5 mg Tablets Active Ingredients Finasteride
Medicine Name Puregon Cartridge 300 IU, 600 IU, 900 IU Active Ingredients Follitropin beta
Medicine Name Rebetol 40 mg/ml oral solution Active Ingredients Ribavirin
Medicine Name Remicade Powder for Solution for Infusion Active Ingredients Infliximab
Medicine Name Restandol Active Ingredients Testosterone undecanoate
Medicine Name Simponi 100 mg solution for injection, pre filled pen Active Ingredients Golimumab
Medicine Name Simponi 50 mg solution for injection, pre filled pen Active Ingredients Golimumab
Medicine Name Simponi 50 mg solution for injection, pre filled syringe Active Ingredients Golimumab
Medicine Name Sinemet 10mg/100mg, Plus 25mg/100mg & 25mg/250mg Tablets Active Ingredients Carbidopa, Levodopa
Medicine Name Sinemet 12.5mg/50mg Tablets Active Ingredients Carbidopa, Levodopa
Medicine Name SINEMET CR 50mg/200mg Prolonged-release Tablets Active Ingredients Carbidopa, Levodopa
Medicine Name Singulair 10mg Film-coated Tablets Active Ingredients Montelukast Sodium
Medicine Name Singulair Paediatric 4mg Oral Granules Active Ingredients Montelukast Sodium
Medicine Name Singulair Paediatric 5mg Chewable Tablets Active Ingredients Montelukast Sodium
Medicine Name Sivextro 200 mg film-coated tablets Active Ingredients Tedizolid phosphate
Medicine Name Sivextro 200 mg powder for concentrate for solution for infusion Active Ingredients Tedizolid phosphate
Medicine Name Steglatro 5 mg and 15 mg film-coated tablets Active Ingredients Ertugliflozin
51 - 75 of 84 items.Total: 4 pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 13 November 2019 PIL

Reasons for updating

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

Change to section 2 and section 6

 

Updated on 13 November 2019 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Safety Label Update to include text regarding an increased risk of myopathy and/or rhabdomyolysis by co-administration of HMGCoA reductase inhibitors and daptomycin for the sections 4.4 and 4.5

Updated on 17 June 2019 SmPC

Reasons for updating

  • Improved presentation of SmPC

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Converted the SPC from word format to pdf file format

 

 

Updated on 15 October 2018 PIL

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision
  • Change to other sources of information section

Updated on 11 June 2018 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Addition of information regarding anaphylaxis added to section 4.8 of the SPC

Updated on 11 June 2018 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 6 April 2018 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 6 April 2018 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

-          Update to section 4.4 and section 4.5  to include text regarding an increased risk of myopathy with interacting drugs that interfere with statin metabolism and/or transporter pathways.

-          Update to section 4.5 to include reference to consult the prescribing information of all concomitantly used drugs to obtain further information about their potential interactions with simvastatin and/or the potential for enzyme or transporter alterations and possible adjustments to dose and regimens

-          Insertion of the following text (highlighted in red) in section 4.5 / subsection Fusidic acid:

If treatment with systemic fusidic acid is necessary, simvastatin treatment should be discontinued throughout the duration of the fusidic acid treatment. Also see section 4.4.’

-          Updates to SPC in line with the QRD template and editorial changes also undertaken.

Updated on 5 April 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 5 April 2018 PIL

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision
  • Change to other sources of information section
  • Correction of spelling/typing errors

Updated on 1 August 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 1 August 2017 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Insertion of the following text in section 4.2 (inserted text highlighted in red):

‘Posology

The dosage range is 5‑80 mg/day of simvastatin given orally as a single dose in the evening.’

Editorial updates undertaken to sections 4.4 & 6.5.


Updated on 31 July 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 31 July 2017 PIL

Reasons for updating

  • Change to section 3 - dose and frequency
  • Change to section 6 - date of revision
  • Change to other sources of information section

Updated on 10 May 2017 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

SPC change details:

Update to sections 4.2, 4.4, 4.5 & 5.2 to include information on drug-drug interaction of BCRP inhibitors with HMG-CoA reductase inhibitors (statins) and on concomitant use of HMG-CoA reductase inhibitors (statins) with fusidic acid

Updated on 9 May 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 6 - date of revision

Updated on 5 August 2015 PIL

Reasons for updating

  • Change to date of revision

Updated on 29 July 2015 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Additional warning regarding "very rare reports of an immune-mediated necrotizing myopathy (IMNM) during or after treatment with some statins" has been added

Updated on 24 July 2015 PIL

Reasons for updating

  • Change to warnings or special precautions for use

Updated on 12 March 2015 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

SPC sections have changed: 4.2, 4.3, 4.4, 4.5, 4.6, 4.8, 5.2, 10
Updated warnings/interactions; Change of contraindications

Added warnings regarding taking Zocor with lomitapide and patients with HoFH; Cobicistat added as interacting agent




Updated on 12 March 2015 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to date of revision
  • Addition of information on reporting a side effect.

Updated on 25 February 2015 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to date of revision
  • Discontinuation of one or more strengths

Updated on 22 January 2015 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 5.2 - Pharmacokinetic properties

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Sections 4.4, 4.5 & 5.2 - 
Reasons for submission: Approval of Type II Work-Sharing Variation- Notification regarding increased risk of myopathy with the SLCO1B1 gene

 

Updated on 27 August 2014 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Sections 4.4, 4.5, 10

Updated on 20 January 2014 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to side-effects
  • Change to date of revision

Updated on 16 May 2013 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Updates to Sections 4.3, 4.4, 4.5, 10.

Updated on 15 March 2013 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Sections 7 and 10 - Updated MA Holder address

Updated on 19 December 2012 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision

Updated on 5 November 2012 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Sections 4.3, 4.4, 4.5, 4.8, 10 

Updated contraindications

 

Updated on 4 October 2012 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision

Updated on 8 August 2012 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.4 - addition of information regarding diabetes and statins
4.8 - addition of new side effect

Updated on 1 June 2012 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision

Updated on 6 March 2012 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Update to Sections: 4.2, 4.3, 4.4, 4.5, 4.8, 10.
Updated adverse events / contraindications.

 

Updated on 13 April 2011 PIL

Reasons for updating

  • Change to side-effects

Updated on 10 March 2011 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to storage instructions

Updated on 10 March 2011 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Updated adverse events - Sections 4.4, 4.5, 4.8.

 

Updated on 17 February 2011 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 6.4 - Special precautions for storage

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Additional warnings - Contraindications / updated storage conditions

 

Updated on 7 July 2010 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 7 May 2010 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Change to sections 4.2, 4.4, 4.5, 4.8, 5.1
II25 (safety - Cholesterol, Homocysteine), II28 (safety - based on HPS2 THRIVE)

 

Updated on 6 April 2010 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Change to sections 4.2, 4.4, 4.8, 5.1, 5.2
II23 (insomnia, memory impairment), II27 (paediatric worksharing)

 

 

 

 

Updated on 10 March 2010 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 6.1 - List of excipients

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Change to sections 2 and 6.1 (renewal completion).
More detailed information on excipients.

 

Updated on 15 July 2008 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.2 Posology and method of administration – removal of niacin dose cap
4.4 Special warnings and precautions for use – removal of niacin dose cap and interaction with fusidic acid
4.5 Interaction with other medicinal products and other forms of interaction – removal of niacin dose cap and interaction with fusidic acid
4.8 Undesirable effects – addition of very rarely hepatic failure

Updated on 15 July 2008 PIL

Reasons for updating

  • Change due to harmonisation of patient information leaflet

Updated on 7 February 2008 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

The changes are to Sections 4.2; 4.4 and 4.5.

Updated on 20 September 2007 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

SPC for Zocor - the change is to section 4.8 (to include hepatic failure).

Updated on 16 March 2007 PIL

Reasons for updating

  • Change to marketing authorisation holder

Updated on 19 February 2007 SmPC

Reasons for updating

  • Change to marketing authorisation holder

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Cahnge of PA licence holder from Merck, Sharp and Dohme to Merck Sharp and Dohme Ireland Human Health Ltd

Updated on 12 May 2006 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 12 May 2006 PIL

Reasons for updating

  • Change to drug interactions
  • Change to warnings or special precautions for use

Updated on 16 August 2005 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 17 May 2004 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 5.2 - Pharmacokinetic properties

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 10 December 2003 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 18 November 2003 SmPC

Reasons for updating

  • Change to section 3 - Pharmaceutical form

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 25 September 2003 SmPC

Reasons for updating

  • Correction of spelling/typing errors
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 13 August 2003 SmPC

Reasons for updating

  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.3 - Shelf life

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 19 June 2003 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may be renewed (B)